Immunohistochemistry (IHC)
tumor, breast cancer
TUMOR, BREAST CANCER
Baseline tissue samples from all patients enrolled in the study were tested for NEO-201 expression by IHC. Fifteen of 17 patients had tissue evaluable for IHC, and of these 14/15 had more than 90% tissue stain positive for the NEO-201 antigen with 3 + intensity. One breast cancer patient had 3 + staining in about 20% of the tumor section analyzed (Supplementary Table 